Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/63073

Type
Article
Copyright
Restricted access
Embargo date
2030-31-12
Sustainable Development Goals
10 Redução das desigualdades
Collections
Share

Statistics
Metadata
Show full item record

MOLECULAR PHARMING FOR LOW AND MIDDLE INCOME COUNTRIES
Murad, Sheeba et al. | Date Issued: 2020
Author
Murad, Sheeba
Fuller, Sebastian
Menary, Jonathan
Moore, Cathy
Pinneh, Elizabeth
Szeto, Tim
Hitzeroth, Inga
Freire, Marcos
Taychakhoonavudh, Suthira
Phoolcharoen, Waranyoo
Ma, Julian K. C.
Affilliation
St. George's University of London. Institute for Infection and Immunity. London, UK.
St. George's University of London. Institute for Infection and Immunity. London, UK.
St. George's University of London. Institute for Infection and Immunity. London, UK.
St. George's University of London. Institute for Infection and Immunity. London, UK.
St. George's University of London. Institute for Infection and Immunity. London, UK.
St. George's University of London. Institute for Infection and Immunity. London, UK.
University of Cape Town. Molecular & Cell Biology Department. Biopharming Research Unit. Cape Town, South Africa.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Rio de Janeiro, RJ, Brasil.
Chulalongkorn University. Faculty of Pharmaceutical Sciences. Department of Social and Administrative Pharmacy. Bangkok, Thailand.
Chulalongkorn University. Faculty of Pharmaceutical Sciences. Department of Pharmacognosy and Pharmaceutical Botany. Research Unit for Plant-produced Pharmaceuticals. Bangkok, Thailand.
St. George's University of London. Institute for Infection and Immunity. London, UK.
Abstract
Interest in applications and benefits that Molecular Pharming might offer to Low and Middle Income Countries has always been a potent driver for the research discipline, and a major reason why many scientists entered the field. Although enthusiasm remains high, the reality is that such a game-changing innovation would always take longer than traditional uptake of new technology in developed countries, and be complicated by external factors beyond technical feasibility. Excitingly, signs of increasing interest by LMICS in Molecular Pharming are now emerging. Here, three case studies from Thailand, South Africa and Brazil are used to identify some of the key issues when a new investment into Molecular Pharming manufacturing capacity is under consideration. At present, academic research is not necessarily addressing these issues. Only by understanding the concerns, can members of the academic community contribute to helping the development of Molecular Pharming for LMICs by focusing their research efforts appropriately.
Keywords
Molecular Pharming
Low and Middle Income Countries
LMICS
Brazil
Thailand
Plant biotechnology
 
Publisher
Elsevier
Citation
MURAD, Sheeba et al. Molecular Pharming for low and middle income countries. Current Opinion in Biotechnology, v. 61, p. 53-59, Feb. 2020.
DOI
10.1016/j.copbio.2019.10.005
ISSN
0958-1669